SREBF1 and fatty liver disease: Since insulin is a crucial regulator of SREBP-1c, improvements in insulin sensitivity, potentially facilitated by probiotics, could inhibit fatty acid synthesis, offering additional protection against hepatic steatosis (104, 106).